相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Apolipoprotein A1 deficiency in mice primes bone marrow stem cells for T cell lymphopoiesis
Amber B. Ouweneel et al.
JOURNAL OF CELL SCIENCE (2022)
The Current Status of Research on High-Density Lipoproteins (HDL): A Paradigm Shift from HDL Quantity to HDL Quality and HDL Functionality
Kyung-Hyun Cho
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Inflammatory Mediators in Atherosclerotic Vascular Remodeling
Bryce R. Evans et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Role of Lipoproteins in the Pathophysiology of Breast Cancer
Santhi Latha Pandrangi et al.
MEMBRANES (2022)
Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention
Jian-Di Liu et al.
MEDICINE (2022)
The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
Alexey Meshkov et al.
GENES (2021)
Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis
Jun Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
High density lipoproteins and oxidative stress in breast cancer
Gabriele Mazzuferi et al.
LIPIDS IN HEALTH AND DISEASE (2021)
Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases
Anna Wolska et al.
CELLS (2021)
Mercury Content in Dietary Supplements From Poland Containing Ingredients of Plant Origin: A Safety Assessment
Anna Puscion-Jakubik et al.
FRONTIERS IN PHARMACOLOGY (2021)
Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus
Agnieszka Bielska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Jennifer Behbodikhah et al.
METABOLITES (2021)
Dietary Strategies to Improve Cardiovascular Health: Focus on Increasing High-Density Lipoprotein Functionality
Julia T. Stadler et al.
FRONTIERS IN NUTRITION (2021)
High Density Lipoproteins and Diabetes
Blake J. Cochran et al.
CELLS (2021)
Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance The ERASE Randomized Clinical Trial
Dong-Woo Kang et al.
JAMA ONCOLOGY (2021)
European survey on acute coronary syndrome diagnosis and revascularisation treatment: Assessing differences in reported clinical practice with a focus on strategies for specific patient cases
Anne-Claire Peultier et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2020)
A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE-/-mice
Sanhu Gou et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer's Disease
Dustin Chernick et al.
BIOMOLECULES (2020)
HDL and Reverse Cholesterol Transport Basic Mechanisms and Their Roles in Vascular Health and Disease
Mireille Ouimet et al.
CIRCULATION RESEARCH (2019)
HDL from an Alzheimer's disease perspective
Emily B. Button et al.
CURRENT OPINION IN LIPIDOLOGY (2019)
Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
Karin Kornmueller et al.
MOLECULES (2019)
Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation
Tessa J. Barrett et al.
CIRCULATION (2019)
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes A Systematic Review and Meta-analysis
Elvira D'Andrea et al.
JAMA NETWORK OPEN (2019)
SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux
Wen-Jun Shen et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 80 (2018)
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
Andreas Gille et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines?
K. Ray et al.
EUROPEAN HEART JOURNAL (2018)
APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe(-/-) atherosclerotic mice
Gabriele Romano et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Mendelian randomization: Its impact on cardiovascular disease
Masa-aki Kawashiri et al.
JOURNAL OF CARDIOLOGY (2018)
The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review
Justyna Pordzik et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits
Bradley K. Wacker et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis
Neelam Srivastava et al.
FRONTIERS IN PHYSIOLOGY (2018)
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial A Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA CARDIOLOGY (2018)
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial A Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA CARDIOLOGY (2018)
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
Francois Mach et al.
EUROPEAN HEART JOURNAL (2018)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease
Sofia Fernandez-de Retana et al.
NEUROBIOLOGY OF AGING (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial
Lawrence A. Leiter et al.
DIABETES OBESITY & METABOLISM (2017)
Inflammation, immune activation, and cardiovascular disease in HIV
Eric Nou et al.
AIDS (2016)
Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice
Jerome Robert et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2016)
The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications
Jonathan E. Feig et al.
CORONARY ARTERY DISEASE (2016)
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease
Jeffrey L. Cummings et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease
D. G. Kallend et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2016)
Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice
Nicholas F. Fitz et al.
BRAIN (2015)
HDL re-examined
G. Kees Hovingh et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk
Anouar Hafiane et al.
BBA CLINICAL (2015)
HDL and cardiovascular disease
Daniel J. Rader et al.
LANCET (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cardiovascular effects of statins, beyond lipid-lowering properties
Christos G. Mihos et al.
PHARMACOLOGICAL RESEARCH (2014)
Pitavastatin Increases HDL Particles Functionally Preserved with Cholesterol Efflux Capacity and Antioxidative Actions in Dyslipidemic Patients
Maki Miyamoto-Sasaki et al.
Journal of Atherosclerosis and Thrombosis (2013)
Thematic Review Series: High Density Lipoprotein Structure, Function, and Metabolism Unraveling the complexities of the HDL lipidome
Anatol Kontush et al.
JOURNAL OF LIPID RESEARCH (2013)
The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics
Pedro M. R. Cruz et al.
FRONTIERS IN PHARMACOLOGY (2013)
Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type
Borja Ibanez et al.
ATHEROSCLEROSIS (2012)
Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice
Yong Zhong et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Benjamin F. Voight et al.
LANCET (2012)
HDL dysfunction in diabetes: causes and possible treatments
Dan Farbstein et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2012)
Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Philip J. Barter et al.
CIRCULATION (2011)
ATP-Binding Cassette Transporters A1 and G1, HDL Metabolism, Cholesterol Efflux, and Inflammation: Important Targets for the Treatment of Atherosclerosis
Dan Ye et al.
CURRENT DRUG TARGETS (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pitavastatin: finding its place in therapy
Leiv Ose
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2011)
Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits
Byung H. Simon Cho et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2010)
Effects of hormonal treatment on lipids in patients with cancer
T. D. Filippatos et al.
CANCER TREATMENT REVIEWS (2009)
Liver X receptors as therapeutic targets for managing cholesterol: implications for inflammatory conditions
Yuan Zhang et al.
CLINICAL LIPIDOLOGY (2009)
AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-choteslerol levels: correction of murine ApoA-I deficiency
Stefan F. C. Vaessen et al.
JOURNAL OF GENE MEDICINE (2009)
Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I
Eric T. Alexander et al.
JOURNAL OF LIPID RESEARCH (2009)
Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease
Shaila P. Handattu et al.
NEUROBIOLOGY OF DISEASE (2009)
HDL Metabolism and CETP Inhibition
Rakhi Shah Barkowski et al.
CARDIOLOGY IN REVIEW (2008)
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
LANCET (2008)
Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
Corinna Lebherz et al.
CARDIOVASCULAR DIABETOLOGY (2007)
Diet and lifestyle recommendations revision 2006 - A scientific statement from the American Heart Association Nutrition Committee (vol 114, pg 82, 2006)
Alice H. Lichtenstein et al.
CIRCULATION (2006)
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome
L Simons et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice
M Navab et al.
CIRCULATION (2004)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes - A randomized controlled trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)